Clinical TrialMay 7, 2026, 08:24 AM
AIM ImmunoTech Ampligen Phase 2 ORR 50% in Ovarian Cancer
AI Summary
AIM ImmunoTech announced positive final primary endpoint data from a Phase 2 clinical trial of Ampligen (rintatolimod) in combination with checkpoint inhibition and chemotherapy for recurrent ovarian cancer. The study, a collaboration with the University of Pittsburgh Medical Center and Merck, reported a 50% Objective Response Rate (ORR), including 21% complete responses, and a 79% Clinical Benefit Rate. The median Overall Survival was 32.5 months, with durable responses exceeding 70+ months in some patients and no severe toxicities observed.
Key Highlights
- Ampligen Phase 2 trial showed 50% Objective Response Rate (ORR).
- Trial achieved 21% complete responses in recurrent ovarian cancer.
- Clinical Benefit Rate was 79% in the study.
- Median Overall Survival reached 32.5 months.
- Durable responses exceeded 70+ months in select patients.
- No Grade 4 or 5 toxicities observed in the trial.
- IP protection for Ampligen extends into 2039.